Here are six takeaways:
1. The MYO-1070 study evaluates post-surgical pain management for patients treated with iovera prior to undergoing a total knee replacement; 150 patients were enrolled, and the enrollment target was reached six weeks early.
2. The MYO-0946 study evaluates iovera as a temporary nerve block for patients with chronic knee pain due to osteoarthritis; 180 patients were enrolled.
3. Both studies measure the effect of using the FDA-cleared iovera treatment to freeze the peripheral nerves which transmit pain to the knee.
4. The iovera treatment provides an immediate nerve block that is a non-systematic, non-narcotic solution to blocking pain for an extended period of time.
5. The iovera treatment has been commercially available in the United States since March 2014.
6. Results of the studies will be available later this year.
More articles on devices and implants:
Nationwide Fund Advisors purchases $26.4M Zimmer Biomet stake: 5 key notes
Exactech short interest falls 2% — 5 takeaways
Analysts rate CONMED shares — 4 quick facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
